Q-omics provides the consensus-scored CCT6P4 profile across patient tissues and cancer cell-line models. CCT6P4 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCT6P4 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, CCT6P4 RNA expression shows 6,220 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LUAD, and STAD as cancer lineages where CCT6P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCT6P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCT6P4 survival associations across molecular data types. CCT6P4 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCT6P4 RNA expression–survival associations across cancer types. High CCT6P4 expression shows unfavorable associations in KIRC, LIHC, ACC, THYM and ESCA, but favorable associations in LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify KIRC as the clearest survival context for CCT6P4 RNA expression.
This table summarizes CCT6P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CCT6P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCT6P4 shows lower tumor expression in THCA and higher tumor expression in LUAD, COAD, LIHC and LUSC. The LUAD box plot shows higher CCT6P4 RNA expression in tumor versus normal tissue (log2 FC = +0.028, t-test p < 0.001).
This table shows molecular features associated with CCT6P4 in patient tissues and cancer cell lines. In patient samples, CCT6P4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
